

# Index

## A

AA. *See* Aortic arch  
Aberrant right subclavian artery, 187  
ADAM17, 226  
Adams–Oliver syndrome, 294  
Adipocyte, epicardial-derived cells in formation, 208  
*Adm*, 141–142  
AHF. *See* Anterior heart field  
AKT, postnatal heart growth regulation, 58, 60–62  
Alagille syndrome, 293–294  
Alcohol, congenital heart disease induction, 349–350  
Aldehyde dehydrogenase (ALDH), 349–350  
ALDH. *See* Aldehyde dehydrogenase  
Alk2, 192  
ALK4, 14  
AMPK, 157  
Ang1, 120  
ANK2, 153  
Anterior heart field (AHF), 252  
Antiarrhythmic drugs, congenital heart disease induction, 351  
Anticonvulsants, congenital heart disease induction, 350–351  
Antidepressants, congenital heart disease induction, 351–352  
Aortic arch (AA)  
  development, 186–187, 192  
  mouse models of artery defects, 332–334  
APELIN, 142  
*APJ-CrER*, 125  
*Apln-CrER*, 124  
ARIDIA, 153  
Atrioventricular bundle (AVB), 150, 159  
Atrioventricular canal, development, 23–25, 27, 33–35, 255  
Atrioventricular node (AVN), 150–152, 154–157  
Atrium  
  chamber separation in chicken, 255–256  
  transcription factors in septation, 84–85  
AVB. *See* Atrioventricular bundle  
AVCR2B, 303  
AVN. *See* Atrioventricular node  
Azenfeld–Rieger syndrome, 294

## B

BAF, chromatin remodeling complexes, 86–87  
Bardet–Biedl syndrome, 294

## BMP

BMP2, 155, 250–251, 269  
BMP4, 190–191, 250  
BMP7, 190–191  
BMP10, 160, 268  
  cardiac lineage specification, 11, 31  
*Brachyury*, 102  
*Braveheart*, 103  
BRD4, 99

## C

CAFS. *See* Conotruncal anomaly face syndrome  
Calcineurin, 64  
Calcium flux, contractile activity onset, 76–77  
Canta syndrome, 294  
Cardiac fibroblast  
  cardiomyocyte proliferation role, 177  
  conduction system insulation, 176  
  development  
    endothelial/endocardial-derived fibroblasts, 176  
    epicardial-derived fibroblasts, 171–173, 206  
    gene regulation, 175–176  
    markers, 170–171  
  overview, 169–170  
  prospects for study, 177–178  
Cardiac neural crest (CNC)  
  ablation model, 187, 189  
  aortic arch system development, 186–187, 192  
  cell migration, 191–192  
  congenital heart diseases, 187  
  coronary vessel development, 190  
  delamination, 190–191  
  heart valve development, 189  
  induction and specification, 190  
  innervation and conduction system, 189  
  outflow tract development, 184–186, 192  
  overview, 183–184  
  prospects for study, 196  
  signaling pathways in development, 192–194  
  syndromes, 194–196  
Cardiomyocyte. *See also* Conduction system;  
  Contractile activity onset  
  cell-cycle exit and heart growth, 61–62  
  endocardial cell in development, 228–229  
  epicardial-derived cells in formation, 206, 208  
  fibroblasts in proliferation, 177

## Index

- Cardiomyocyte (*Continued*)
    - long noncoding RNA in cardiac development, 102–106
    - origins, 2–4, 6–7, 11
    - reptiles, 271
  - Cardiopharyngeal field (CPF), 1
  - Cardiopharyngeal progenitor cell (CPC)
    - early markers, 2–3
    - lineage potential
      - heterogeneity of single cells, 6–7
      - tracing studies, 3–6
    - overview, 1–2
    - prospects for study, 14–15
    - specification regulation
      - cardiomyocyte versus skeletal muscle, 13–14
      - lineage specification, 11
      - mesoderm induction, 8–10
      - regional specification, 12–13
  - CARMEN, 104
  - Carpenter syndrome, 295
  - Char syndrome, 295
  - CHARGE syndrome, 195–196, 295
  - CHD. *See* Congenital heart disease
  - CHD3, 87
  - CHD4, 87
  - CHD7, 195, 306
  - Chicken heart development models
    - atrial chamber separation, 255–256
    - cardiac progenitor cell migration and heart tube formation, 249–252
    - conduction system formation, 256–257
    - congenital heart defects, 258
    - endocardial cushion formation and valve development, 254–255
    - epicardial cell layer formation, 253–254
    - gene activity manipulation, 249
    - heart fields, 252–253
    - human relevance, 257–258
    - transgenesis, 247–249
    - ventricular trabeculation and separation, 256
  - CNC. *See* Cardiac neural crest
  - Coffin–Siris syndrome, 295
  - Conduction system
    - anatomy, 150
    - atrioventricular bundle
      - development, 154
      - gene regulation of development and function, 154–159
    - atrioventricular node
      - anatomy and function, 154
      - clinical genetics, 157
      - development, 154
      - gene regulation of development and function, 154–157
      - maintenance, 154
  - development
    - cardiac neural crest, 189
    - chicken, 256–257
    - overview, 34–35, 149
  - electrocardiogram components, 150, 158
  - gap junctions, 151
  - insulation by fibroblasts, 176
  - models for study, 161
  - nervous system control, 151–152
  - prospects for study, 161
  - Purkinje fibers
    - clinical genetics, 160–161
    - development, 160
    - gene regulation of development and function, 160
  - reptiles, 270
  - sinoatrial node
    - anatomy and function, 152
    - clinical genetics, 153–154
    - development, 152
    - gene regulation of development and function, 153
    - maintenance, 152–153
    - therapeutic targeting, 161
    - ventricular conduction system
      - anatomy and function, 157
      - maintenance, 157, 150
- Congenital heart disease (CHD). *See also specific diseases*
- cardiac neural crest, 18
  - chicken models, 258
  - chromosomal aneuploidy, 286–291
  - common variants, 306
  - copy number variation, 291–292
  - environmental causes
    - maternal diseases and infections, 354–356
    - nutritional deficiencies, 352–354
    - prospects for study, 356
    - teratogens, 348–352
  - fruit fly models, 336
  - genetic basis, 284–285
  - genetic testing, 285–286, 306–307
  - induced pluripotent stem cell studies, 336–337
  - mouse models. *See* Mouse models, congenital heart disease
  - overview, 283–284, 323–324, 346–348
  - single gene defects, 292–306
  - Xenopus* models, 241–242
  - zebrafish models, 336
- Conotruncal anomaly face syndrome (CAFS), 194
- Contractile activity onset
- cardiomyocyte
    - contractility apparatus, 74
    - physiology in developing heart, 75–77
  - knockout mouse studies, 71
  - mouse models, 70–74
  - overview, 69–70

- Cornelia de Lange syndrome, 295  
Coronary vessels  
    collateral artery formation after ischemic injury, 124–126  
    endothelium origins after cardiac injury, 121–124  
    fetal development  
        cardiac neural crest, 190  
        endocardium origin, 118–119  
        molecular mechanisms, 119–120  
        proepicardium/epicardium origin, 116–117  
        sinus venous origin, 117–118  
        yolk sac circulating progenitors, 119  
    postnatal development, 120–121  
Costello syndrome, 295  
Coup-TFII, 33  
CPC. *See* Cardiopharyngeal progenitor cell  
CPE. *See* Cardiopharyngeal field  
CPM. *See* Cranial paraxial mesoderm  
Cranial paraxial mesoderm (CPM), chicken, 252–253  
Cri-du-chat syndrome, 288  
CRKL, 292, 332, 334  
CRYPTIC, 303  
CXCL12, 120, 125, 228  
CXCR4, 120, 125, 228  
CXCR7, 226
- D**
- DEANRI, 102  
DGS. *See* DiGeorge syndrome  
Diabetes, maternal disease and congenital heart disease, 354  
DiGeorge syndrome (DGS), 194, 291–292  
Dkk1, 11  
Dkk2, 11  
Down syndrome, 286  
*Drosophila* models, congenital heart disease, 336
- E**
- ECC. *See* Excitation contraction coupling  
ECG. *See* Electrocardiogram  
EED, 89  
Electrocardiogram (ECG), components, 150, 158  
ELN, 292, 337  
EMP. *See* Erythromyeloid progenitor  
EMT. *See* Epithelial-to-mesenchymal transition  
Endocardial cell  
    cardiomyocyte development, 228–229  
    cell fate analysis, 221–222  
    defects in disease, 229  
    endothelial cell development, 227–228  
    heart valve  
        endocardial cushion formation and signaling  
            NFATC1, 225  
            Notch, 223  
            overview, 221–223  
            Sox9, 226  
            TGF- $\beta$ , 223  
            VEGF, 224–225  
        mature heart valve structure–function relationships, 227  
        post-epithelial-to-mesenchymal transition development, 226  
    origins, 2–4, 6–7, 11, 220–221  
    overview, 219–220  
    plasticity after birth  
        heart valves, 229–230  
        myocardium, 229  
    prospects for study, 230  
EndoMT. *See* Endothelial-to-mesenchymal transition  
Endothelial cell  
    endocardial cell in development, 227–228  
    long noncoding RNA in cardiac development, 106–107  
    lymphatic endothelial cell.  
        *See* Lymphatic system, cardiac  
    Endothelial-to-mesenchymal transition (EndoMT), 122  
Eomes, 100–101  
EP300, 90  
EPDC. *See* Epicardial-derived cell  
Epicardial-derived cell (EPDC)  
    cell fates  
        adipocyte formation, 208  
        cardiomyocyte formation, 206, 208  
        fibroblast formation. *See* Cardiac fibroblast  
        overview, 207–208  
        smooth muscle cell formation, 206  
    heterogeneity, 209  
    markers, 207, 209  
    origins, 2–3, 203–205  
Epicardium  
    chicken, 253–254  
    epithelial-to-mesenchymal transition, 203–205  
    extracellular matrix, 212  
    origins, 202–203  
    overview, 201–202  
    prospects for study, 212  
    signaling  
        erythropoietin, 210–211  
        FGF, 210  
        IGF2, 211  
        Notch, 211  
        retinoic acid, 209–210  
        Shh, 210  
        VEGFA, 211  
        VEGFC, 211

## Index

### Epicardium (*Continued*)

Wnt, 211–212

### Epigenetics, heart development

#### chromatin

dynamics, 85

remodeling complexes, 86–87

*cis*-regulatory elements, 85–86

nucleosome remodeling and histone

deacetylation, 87–88

Polycomb repressor complexes, 88–91

prospects for study, 91

### Epithelial-to-mesenchymal transition (EMT)

cardiac fibroblasts, 173–175, 177

cardiac neural crest, 190

chicken, 250, 254

endocardial cell, 222–226

epicardium formation, 203–205

ERR $\gamma$ , 60

Erythromyeloid progenitor (EMP), 119

Erythropoietin, 210–211

ETV1, 160

*Evx1*, 102

Excitation contraction coupling (ECC),

development, 75

EZH2, 89

## F

FASDH. *See* Fetal alcohol spectrum disorder

*Fendrr*, 101

Fetal alcohol spectrum disorder (FASDH), 349

Fever, maternal infection and congenital

heart disease, 355–356

FGF2, 11

FGF8, 11, 192

FGF9, 210

Fgf10, 25

FGF16, 210

FGF20, 210

FHF. *See* First heart field

Fibroblast. *See* Cardiac fibroblast

First heart field (FHF)

cardiopharyngeal progenitor cell heterogeneity, 6–7

chicken, 249

final structures and development, 2, 28–30

Flk1, 2–3

FOG2, 87

Folic acid, deficiency and congenital heart disease

induction, 352–353

*FOXA2*, 102

*FOXC1*, 334

*FOXC2*, 334

*FoxD3*, 191

*FOXF1*, 101

*FOXH1*, 334

Fragile X syndrome, 296

## G

### GATA4

atrial septation, 84–85

atrioventricular node development, 156–157

chromatin occupancy during heart

development, 82–84

FOG2 interactions, 87

mouse models of septation defects, 325, 329

mutations, 304

mutations, 81

PRC interactions, 91

GATA5, mouse models of valve malformations, 331–332

### GATA6

atrioventricular node development, 156–157

mouse models of valve malformations, 331–332

GCN5, 101

*GDF1*, 303–304

Gsc, 100

## H

Hand1, 103, 173

Hand2, 101, 103–105, 173–174

HAS2, 106

Haunt, 101

*HBL1*, 102

*Hcn4*, 152–153, 157

HDAC1, 87

HDAC2, 87–88

HDAC3, 159

### Heart size

fetal to adult heart growth, 58–59

metabolic changes during heart growth, 59–61

organism mass dependence, 53–54

prospects for study, 64–65

regulation during cardiogenesis

Hippo, 55–58

IGF, 57–58

overview, 54–56

Yap, 55–58

regulation during postnatal growth

cardiomyocyte cell-cycle exit, 61–62

hypertrophic growth, 62–64

### Heart tube

contractile activity development, 69–73, 76

formation, 25–31

### Heart valves

cardiac neural crest in development, 189

chicken development, 254–255

endocardial cell

endocardial cushion formation and signaling

NFATC1, 225

Notch, 223

overview, 221–223

Sox9, 226

TGF- $\beta$ , 223

VEGF, 224–225  
post-epithelial-to-mesenchymal transition  
  development, 226  
mature heart valve structure–function  
  relationships, 227  
plasticity after birth, 229–230  
mouse models of malformations, 327, 330–332  
reptiles, 266, 270  
Hedgehog, 34  
Heterotaxy syndrome (HTX), 303  
HEY1, 157  
HEY2, 157, 160, 270  
HIF-1 $\alpha$ , 60  
Hippo  
  cardiac fibroblast development, 174  
  heart size regulation, 55–58  
His bundle. *See* Atrioventricular bundle  
HLHS. *See* Hypoplastic left heart syndrome  
Holt–Oram syndrome (HOS), 157, 293, 296, 302  
HOPX, 160  
HOS. *See* Holt–Oram syndrome  
*HoxB*, 102  
HTX. *See* Heterotaxy syndrome  
Hyperhomocysteinemia, congenital heart disease  
  induction, 353  
Hyperthermia, maternal infection and congenital  
  heart disease, 355–356  
Hypoplastic left heart syndrome (HLHS), 283,  
  334–335, 337  
Hypoxia, congenital heart disease induction, 350

## I

IGF  
  heart size regulation, 57–58  
  IGF2, 211  
  postnatal hypertrophic cardiac growth regulation, 62  
Induced pluripotent stem cell (iPSC), congenital  
  heart disease models, 336–337  
Interrupted aortic arch, type B, 187, 195, 292  
iPSC. *See* Induced pluripotent stem cell  
IRX3, 160  
ISL1, 27, 153

## J

Jacobsen syndrome, 289  
JAG1, 293  
Johanson–Blizzard syndrome, 296

## K

Kabuki syndrome, 296  
Kleefstra syndrome, 289, 297  
Klf2, 35  
Koolen–de Vries syndrome, 290, 297

## L

Left ventricle (LV), origins, 2, 6  
LEFTYA, 303  
lncRNA. *See* Long noncoding RNA  
Loeys–Dietz syndrome, 297  
Long noncoding RNA (lncRNA)  
  cardiac progenitor cells and cardiomyocytes,  
    102–106  
  endothelial cell, 106–107  
  functional overview, 98–99  
  gene regulatory networks in cardiac  
    development, 97–98  
  mesoderm specification, 101–102  
  pluripotency and developmental  
    competence, 99–101  
  prospects for study, 107–109  
  smooth muscle cell, 106  
IV. *See* Left ventricle  
Lymphatic system, cardiac  
  fetal development  
    cellular origins, 137–140  
    development and growth, 136–137  
    formation mechanisms, 133–136  
  functional overview, 131–132  
  myocardial infarction  
    lymphangiogenesis, 140–141  
    therapeutic targeting, 141–142  
  structure and function, 132–133  
LYVE1, 134

## M

*MALAT1*, 106–107  
*MAML1*, 223  
*MAPK1*, 292  
Marfan syndrome, 298  
MED1, 99  
Merlin, 58  
*Mesp1*, cardiopharyngeal progenitor  
  cell expression, 2–4, 6–7, 9–11  
*Mesp2*, 9  
*Meteor*, 100–101  
*Mhrt*, 106  
MI. *See* Myocardial infarction  
MIB1, 229  
*MIR1*, 102  
MLL2, 306  
Mouse models, congenital heart disease  
  complex defects, 328, 334–335  
  conotruncal and aortic arch artery  
    defects, 327–328, 332–334  
  overview, 323–324  
  septation defects, 324–327, 329–330  
  valve malformations, 327, 330–332  
Mowat–Wilson syndrome, 298  
MTA1, 87–88

## Index

- MYH6, 106, 153–154, 306  
MYH7, 106, 306  
Myhre syndrome, 298  
Myocardial infarction (MI), cardiac lymphatics  
  lymphangiogenesis, 140–141  
  therapeutic targeting, 141–142  
MYOCARDIN, 106  
MYOD, 256  
MYOSLID, 106
- N**
- NAD, deficiency and congenital heart disease  
  induction, 353  
Nanog, 101  
Neural crest. *See* Cardiac neural crest  
NFI1, 298  
NFAT, 64  
NFATC1, 171, 173, 220, 225  
Nfat1-Cre, 118–119, 121  
NFKB1, 161  
Nicotinamide, deficiency and congenital  
  heart disease induction, 353  
Nkx2–5  
  atrial septation, 84  
  atrioventricular node development, 157  
  cardiac cell expression, 1, 4, 9, 14, 25, 81  
  chicken development, 251  
  chromatin occupancy during heart  
    development, 84–85  
  mouse models of septation defects, 325, 329  
  mutations, 304  
Noonan syndrome, 298–299, 302  
NOTCH, 104, 192, 211, 223, 228–229, 337  
  cardiac lineage specification, 11, 31  
  mouse models of valve malformations, 330  
  mutations, 304  
  NOTCH2, 293  
Nppa, 270–271  
Npr3, 119  
Npr3-CrER, 124  
NRP2, 135  
NuRD, 87–88
- O**
- Obesity, maternal disease and congenital  
  heart disease, 354–355  
OFT. *See* Outflow tract  
Osr1, 34  
Outflow tract (OFT). *See also* Cardiac neural crest  
  chicken, 243–255  
  high-resolution episcopic microscopy of  
    development  
    architecture, 44–45  
    position change during cardiac  
    development, 43–44  
  lymphatic system, 139  
  origins, 2, 6  
  reptiles, 273  
Oxidative stress, cardiomyocyte development, 60
- P**
- p53, 122  
Pacemaker cell, 150, 152  
Pax3, 190  
Pax7, 190  
PCGC. *See* Pediatric Cardiac Genomics Consortium  
PCNA, 271  
PCR2, 101  
PDGFR $\alpha$ , 2–3, 172–175  
PDGFR $\beta$ , 172–174  
PE. *See* Proepicardial organ  
Pediatric Cardiac Genomics Consortium (PCGC), 335  
Persistent truncus arteriosus (PTA), 187, 195  
Peters plus syndrome, 299  
PGC-1, 60  
Phelan–McDermid syndrome, 290  
Phenylketonuria (PKU), congenital  
  heart disease association, 355  
PITX2, 101, 153, 253  
PKD1, 299  
PKU. *See* Phenylketonuria  
Podoplanin, 134–135  
PRC1, 88–89, 91  
PRC2, 89–90  
Primitive streak, 7  
PRKAG2, 157  
Proepicardial organ (PE), 202–203, 253  
PROX1, 134, 136, 159  
PTA. *See* Persistent truncus arteriosus  
Purkinje fibers  
  clinical genetics, 160–161  
  development, 160  
  gene regulation of development and function, 160
- Q**
- QH1, 222
- R**
- RA. *See* Retinoic acid  
RASopathy, 302  
Reptile heart development models  
  circulation, 266  
  developmental stages, 268  
  genomes, 267–268  
  heart chambers, 266  
  heart development  
    cardiomyocytes, 271  
    septation, 271–275  
    transcription factors, 268–271

- heart valves, 266
- mammalian heart similarities, 267
- overview, 263, 265
- rationale for study, 265–266
- ventricular function, 267
- vertebrate phylogeny, 264
- Retinoic acid (RA)
  - cardiac lineage specification, 11–13
  - congenital heart disease induction, 348–349
  - epicardium signaling, 209–210
- Right ventricle (RV), origins, 2, 7
- Roberts syndrome, 300–301
- ROCK, 252
- Rubella, maternal infection and congenital heart disease, 355
- Rubinstein–Taybi syndrome, 301
- RV. *See* Right ventricle
- Ryanodine receptor (RyR), 76–77
- RYBP, 91
- RyR. *See* Ryanodine receptor
  
- S**
- SAN. *See* Sinoatrial node
- Scleraxis, 175
- SCN5A, 153
- Second heart field (SHF)
  - cardiac neural crest signaling interactions, 192–194
  - cardiopharyngeal progenitor cell heterogeneity, 6–7
  - chicken, 252
  - final structures and development, 2, 28–30
  - lymphatic system, 139
  - outflow tract development, 184–186
- Selective serotonin reuptake inhibitors (SSRIs), congenital heart disease induction, 351–352
- SENCR*, 106
- SHF. *See* Second heart field
- Shh, 210
- Short QT syndrome, 160
- SHOX2, 11, 153
- Sifrim–Hitz–Weiss syndrome, 301
- Sinoatrial node (SAN), 150–154
- Sirt1*, 105
- Six2*, 7
- SMAD1, 351
- Smarcd3, 3–4
- SMC. *See* Smooth muscle cell
- SMILR*, 106
- Smith–Lemli–Opitz syndrome, 301
- Smooth muscle cell (SMC)
  - epicardial-derived cells in formation, 206
  - long noncoding RNA in cardiac development, 106
  - origins, 2, 4, 6
- SNAIL, 253
- Sodium/calcium exchanger, 76–77
  
- Sotos syndrome, 301
- SOX2, 102
- SOX9, 171, 226
- Sox10, 191
- Sox17*, 100, 304
- SP4, 159
- SSRIs. *See* Selective serotonin reuptake inhibitors
  
- T**
- TAZ, 56
- T-box transcription factor, 2
- TBX1, 14, 34, 192–195, 253, 292, 332, 334
- TBX2, 156–157, 269
- TBX3, 11, 153, 156, 159–160, 269
- TBX5, 34, 81–85, 87, 153, 156, 159–160, 253, 272, 293, 302, 325, 329
- TBX18, 11, 23, 34, 152, 202–203, 206, 253
- TBX20, 87, 156
- Tcf21, 175–176, 201
- Tetralogy of Fallot (TOF), 187, 195, 306–307
- TGF- $\beta$ , 223, 229–230
- Thalidomide, congenital heart disease induction, 348
- Thyroid hormone, postnatal hypertrophic cardiac growth regulation, 62
- TIAR, 109
- TOF. *See* Tetralogy of Fallot
- Townes–Brocks syndrome, 301
- Trim72*, 105
- Trisomy 13, 286, 291
- Trisomy 18, 286, 291
- Trisomy 21. *See* Down syndrome
- TRRAP2 $\alpha$ , 274
- Trunk ventral cell (TVC), 7
- Turner syndrome, 287, 291
- TVC. *See* Trunk ventral cell
  
- U**
- Uph*, 104–105
  
- V**
- Valves. *See* Heart valves
- VCAM1, 173
- VCFS. *See* Velocardiofacial syndrome
- VCS. *See* Ventricular conduction system
- VE-cadherin, coronary vessel development, 117–118
- VEGF
  - cardiac lineage specification, 11
  - VEGFA, 120, 211, 228
  - VEGFC, 120, 134–135, 141, 211, 228
  - VEGFD, 134
- VEGFR2, 123
- VEGFR3, 134–136, 140–141
- Velocardiofacial syndrome (VCFS), 194, 291
- Venous pole, origins, 2

## Index

- Ventricular conduction system (VCS), 150, 157, 159
- Ventricular septation
- chicken, 256
  - high-resolution episcopic microscopy, 42–50
  - interventricular communication closure, 47–50
  - mouse models of septation defects, 324–327, 329–330
  - outflow tract
    - architecture, 44–45
    - position change during cardiac development, 43–44
  - overview, 41–42
  - pulmonary and aortic channel separation, 46–47
  - reptiles, 271–275
- Vitamin A
- congenital heart disease induction, 348–349
  - deficiency and congenital heart disease induction, 352
- Vitamin D, deficiency and congenital heart disease induction, 353–354
- W**
- WDR5, 101
- Weill–Marchesani syndrome, 301
- Williams–Beuren syndrome, 288, 292
- Wisper*, 109
- Wnt, 211–212
- WNT6, 252
- WNT8c, 253
- WT1, 11, 174–175, 253
- X**
- Xenopus* cardiovascular models
- congenital heart disease models, 241–242
  - embryology, 239
  - overview, 237–239
  - regeneration studies, 241
  - species comparison and complementary approaches, 240–241
  - stem cell experiments, 239–240
  - transgenic frogs, 241
- Y**
- Yap, heart size regulation, 55–58
- Ysp1, 35
- Z**
- Zebrafish models, congenital heart disease, 336
- ZIC3, 303